[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,668,281
  • Shares Outstanding, K 139,722
  • Annual Sales, $ 67,670 K
  • Annual Income, $ -412,690 K
  • EBIT $ -421 M
  • EBITDA $ -405 M
  • 60-Month Beta 1.81
  • Price/Sales 23.21
  • Price/Cash Flow N/A
  • Price/Book 2.18

Options Overview Details

View History
  • Implied Volatility 85.43% (+5.33%)
  • Historical Volatility 65.92%
  • IV Percentile 29%
  • IV Rank 17.32%
  • IV High 154.61% on 10/27/25
  • IV Low 70.94% on 08/20/25
  • Expected Move (DTE 12) 1.25 (10.46%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 2,517
  • Volume Avg (30-Day) 2,728
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 79,877
  • Open Int (30-Day) 81,506
  • Expected Range 10.69 to 13.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.80
  • Number of Estimates 7
  • High Estimate $-0.66
  • Low Estimate $-0.89
  • Prior Year $-0.92
  • Growth Rate Est. (year over year) +13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.15 +17.64%
on 07/28/26
17.16 -30.42%
on 07/09/26
-5.49 (-31.50%)
since 07/07/26
3-Month
10.15 +17.64%
on 07/28/26
18.48 -35.39%
on 07/02/26
-1.77 (-12.91%)
since 05/07/26
52-Week
7.95 +50.19%
on 11/21/25
28.25 -57.73%
on 10/20/25
+0.48 (+4.19%)
since 08/07/25

Most Recent Stories

More News
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.94 (+6.23%)
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S....

NTLA : 11.94 (+6.23%)
Intellia Therapeutics: The Window Between Clinical Promise and Commercial Reality Is Closing

Barchart Research What to Expect from NTLA Earnings NTLA Generated August 5, 2026 Current Price $10.97 EPS Estimate $$-0.80 Consensus Rating Moderate Buy Average Move 6.59% Intellia Therapeutics: The Window...

NTLA : 11.94 (+6.23%)
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.94 (+6.23%)
Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears

WOLF is now Wall Street's most shorted stock. Here's why bears keep piling on even after Wolfspeed's big debt overhaul.

SOUN : 8.02 (+13.28%)
RNECY : 11.9700 (+4.00%)
WOLF : 32.87 (+19.14%)
NTLA : 11.94 (+6.23%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.94 (+6.23%)
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published...

NTLA : 11.94 (+6.23%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.94 (+6.23%)
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 11.94 (+6.23%)
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE...

NTLA : 11.94 (+6.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 12.80
2nd Resistance Point 12.44
1st Resistance Point 12.19
Last Price 11.94
1st Support Level 11.58
2nd Support Level 11.22
3rd Support Level 10.97

See More

52-Week High 28.25
Fibonacci 61.8% 20.50
Fibonacci 50% 18.10
Fibonacci 38.2% 15.70
Last Price 11.94
52-Week Low 7.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.